SCHEMBL3460280

SCHEMBL3460280

CC(=NNc1ccc(C(F)(F)F)cc1)c1nc(-c2cccc(C(=O)NCc3ccccc3)c2)cnc1N

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 1/20 0.49
PIK3CA P42336 1/20 0.49
PIK3CG P48736 1/20 0.49
ATR Q13535 10/20 0.49
LDHA P00338 1/20 0.45
LDHB P07195 1/20 0.45
MRGPRX4 Q96LA9 1/20 0.44
EPHB4 P54760 1/20 0.43
MAPK1 P28482 1/20 0.43
JAK2 O60674 1/20 0.43
MAP4K4 O95819 1/20 0.43
CHEK2 O96017 1/20 0.43
PRKCG P05129 1/20 0.43
CDK1 P06493 1/20 0.43
FES P07332 1/20 0.43
RET P07949 1/20 0.43
ROS1 P08922 1/20 0.43
FER P16591 1/20 0.43
FLT1 P17948 1/20 0.43
AXL P30530 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3460279 1.00 PIK3CD (0.49) PIK3CDPIK3CAPIK3CGATRLDHA
SCHEMBL3461024 0.92 ATR (0.57) ATRLDHALDHB
SCHEMBL3461031 0.92 ATR (0.57) ATRLDHALDHB
SCHEMBL3462343 0.90 ATR (0.53) ATRLDHALDHBJAK2MAP4K4
SCHEMBL3462344 0.90 ATR (0.53) ATRLDHALDHBJAK2MAP4K4
SCHEMBL3461249 0.90 ATR (0.52) ATRLDHALDHBJAK2MAP4K4
SCHEMBL3461245 0.90 ATR (0.52) ATRLDHALDHBJAK2MAP4K4
SCHEMBL3460057 0.90 HTR2C (0.51) PIK3CDPIK3CAPIK3CGATRLDHA
SCHEMBL3460060 0.90 HTR2C (0.51) PIK3CDPIK3CAPIK3CGATRLDHA
SCHEMBL3462040 0.90 ATR (0.51) ATRLDHALDHBJAK2MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060211709-A1 Protein kinase modulators and methods of use EXELIXIS, INC. 2006-09-21 US claimed
EP-1501514-B1 PROTEIN KINASE MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2012-12-19 EP disclosed
US-7704995-B2 Protein kinase modulators and methods of use EXELIXIS, INC. (US) 2010-04-27 US disclosed
US-20060211709-A1 Protein kinase modulators and methods of use EXELIXIS, INC. 2006-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211709-A1 Protein kinase modulators and methods of use GRK2, MAP4K2, MAPKAPK2 PIK3CD 375/4885PIK3CA 463/4885PIK3CG 477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.